Author

Michael A. Minnier

Observed name: Michael Minnier

Institution: Spark Therapeutics (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Spark Therapeutics (United States)

ORCID: 0000-0001-6194-0520

Observed ORCID: 0000-0001-6194-0520

OpenAlex ID: A5078971764

Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes

2019 · Xiao Xiao, Aimin Tang, et al. · mAbs · 41

Profiling of hMPV F-specific antibodies isolated from human memory B cells

2022 · Xiao Xiao, Arthur Fridman, et al. · Nature Communications · 30

Inhibition of IFNAR-JAK signaling enhances tolerability and transgene expression of systemic non-viral DNA delivery

2025 · Sujata Senapati, Thais B. Bertolini, et al. · Molecular Therapy — Nucleic Acids · 13

DNA delivered by lipid nanoparticles induces CD8+ T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

2026 · Seoyun Yum, Alba Rodríguez-Garcia, et al. · JCI Insight · 3

Development of a microneutralization assay for HSV-2

2021 · Melanie S. Horton, Michael Minnier, et al. · Journal of Virological Methods

Works count: 5

Citation count: 87

H-index: 3

I10-index: 3